Skip to main content

Table 1 Pharmacokinetics profile of single oral dosing RO9021 in mouse

From: Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy

Dose

Cmax(nM)

Tmax(hours)

T1/2(hours)

AUC (hour*nM)

45 mg/kg

5,763.69

0.50

3.54

35,804.26

5 mg/kg

694.52

1.00

4.34

3,847.84

  1. Cmax, maximum plasma concentration; Tmax, time after administration of a drug when the maximum plasma concentration is reached; T1/2, half-life; AUC, area under the curve.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us